UBS AM’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $46.9M | Sell |
964,690
-988,061
| -51% | -$48.1M | 0.01% | 720 |
|
|
2025
Q1 | $66.5M | Buy |
1,952,751
+1,262,560
| +183% | +$43M | 0.02% | 626 |
|
|
2024
Q4 | $27.2M | Buy |
690,191
+13,865
| +2% | +$546K | 0.01% | 839 |
|
|
2024
Q3 | $31.8M | Sell |
676,326
-17,632
| -3% | -$828K | 0.01% | 791 |
|
|
2024
Q2 | $37.5M | Buy |
693,958
+583,493
| +528% | +$31.5M | 0.01% | 682 |
|
|
2024
Q1 | $7.53M | Buy |
110,465
+14,515
| +15% | +$989K | ﹤0.01% | 1100 |
|
|
2023
Q4 | $6.01M | Buy |
95,950
+2,825
| +3% | +$177K | ﹤0.01% | 1174 |
|
|
2023
Q3 | $4.23M | Buy |
93,125
+10,839
| +13% | +$492K | ﹤0.01% | 1287 |
|
|
2023
Q2 | $3.72M | Hold |
82,286
| – | – | ﹤0.01% | 1366 |
|
|
2023
Q1 | $3.72M | Buy |
82,286
+6,380
| +8% | +$289K | ﹤0.01% | 1366 |
|
|
2022
Q4 | $3.09M | Buy |
75,906
+120
| +0.2% | +$4.88K | ﹤0.01% | 1346 |
|
|
2022
Q3 | $4.95M | Sell |
75,786
-57,368
| -43% | -$3.75M | ﹤0.01% | 1206 |
|
|
2022
Q2 | $8.09M | Buy |
133,154
+13,827
| +12% | +$840K | ﹤0.01% | 1045 |
|
|
2022
Q1 | $7.49M | Sell |
119,327
-206
| -0.2% | -$12.9K | ﹤0.01% | 1182 |
|
|
2021
Q4 | $9.06M | Buy |
119,533
+5,113
| +4% | +$387K | ﹤0.01% | 1161 |
|
|
2021
Q3 | $12.8M | Sell |
114,420
-2,793
| -2% | -$313K | 0.01% | 997 |
|
|
2021
Q2 | $19M | Sell |
117,213
-23,841
| -17% | -$3.86M | 0.01% | 898 |
|
|
2021
Q1 | $17.2M | Buy |
141,054
+34,308
| +32% | +$4.18M | 0.01% | 901 |
|
|
2020
Q4 | $16.3M | Sell |
106,746
-13,846
| -11% | -$2.12M | 0.01% | 899 |
|
|
2020
Q3 | $10.1M | Sell |
120,592
-18,438
| -13% | -$1.54M | 0.01% | 939 |
|
|
2020
Q2 | $10.2M | Buy |
139,030
+8,702
| +7% | +$640K | 0.01% | 901 |
|
|
2020
Q1 | $5.53M | Buy |
+130,328
| New | +$5.53M | ﹤0.01% | 1021 |
|